Biological activity and molecular docking studies of some new quinolines as potent anticancer agents

Tuğba Kul Köprülü*, Salih Ökten*, Vildan Enisoğlu Atalay, Şaban Tekin, Osman Çakmak

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


Abstract: The objective of this study is to investigate the antiproliferative and cytotoxic properties and the action mechanism of substituted quinoline and tetrahydroquinolines 3, 4, 5, 7, and 8 against rat glioblastoma (C6), human cervical cancer (HeLa), human adenocarcinoma (HT29) cancer cell lines by BrdU Cell Proliferation ELISA, Lactate Dehydrogenase, DNA laddering and Topoisomerase I assays. The results of the study showed that 6,8-dibromotetrahydroquinoline 3 possess in vitro antiproliferative activity against C6, HeLa, and HT29 cell lines while morpholine/piperazine substituted quinoline 7 and 8 showed selective antiproliferative activity on C6 cell line with IC50 values 47.5 and 46.3 µg/mL, respectively. Moreover, 6,8-dibromoTHQ 3 caused DNA fragmentation while it did not inhibit the Topoisomerase I (Topo I) enzyme. On the other hand, compound 8 did not cause DNA laddering while 8 inhibited the Topo I enzyme. According to these results, 6,8-dibromoTHQ 3 stimulates apoptosis on the C6 cell line while 6,8-dibromo-3-morhonilylquinoline (8) inhibits the Topo I enzyme to cause antiproliferative activity. Graphic abstract: [Figure not available: see fulltext.].

Original languageEnglish
Article number84
JournalMedical Oncology
Issue number7
Publication statusPublished - Jul 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021, Springer Science+Business Media, LLC, part of Springer Nature.


  • Anticancer activity
  • Cytotoxicity
  • Molecular docking
  • Quinoline
  • Tetrahydroquinoline


Dive into the research topics of 'Biological activity and molecular docking studies of some new quinolines as potent anticancer agents'. Together they form a unique fingerprint.

Cite this